AbstRACt: Generalized lipodystrophy (GL) is a rare inherited or acquired disease characterized by widespread loss of subcutaneous fat, leading to leptin deficiency, ectopic fat deposition, and severe metabolic abnormalities. Previous studies have shown the benefit of leptin replacement (metreleptin) in amelio rating metabolic complications, but little is known about the experience of metreleptin treatment outside of a research setting. We report on postmarketing clinical experience with metreleptin therapy in three patients with GL and marked hypoleptinemia, uncontrolled diabetes, and hypertriglyceridemia. After metreleptin treatment for 12-168 weeks, the mean glycated hemoglobin decreased from 10.9% to 5.8%, and serum triglycerides were normalized (a mean decline of 90%). These benefits were observed within weeks of starting therapy, were durable, and were accompanied by subjective improvements in qual ity of life, decreased need for concomitant medications, and no significant adverse effects. Metreleptin was safe and effective in normalizing certain severe metabolic abnormalities in the clinic setting.
Introduction
Generalized lipodystrophy (GL) is categorized as a rare congenital generalized lipodystrophy (CGL) or acquired gene ralized lipodystrophy (AGL) disease characterized by wide spread loss of adipocytes, leading to leptin deficiency, ectopic fat deposition, and severe metabolic abnormalities (insulin resistance, diabetes, and/or hypertriglyceridemia). 1, 2 In women with insulin resistance and hypoleptinemia, polycystic ovarian syndrome, hyperandrogenism, and amenorrhea are very com mon. 3 Conventional glucose and lipidlowering medications do not address the underlying leptin deficiency and are often inadequate at addressing severe metabolic abnormalities. 1 Metreleptin is a recombinant human leptin analog that binds to and activates the leptin receptor, and it is the only US Food and Drug Administrationapproved treatment for patients with CGL or AGL as an adjunct to diet and as replacement therapy to treat complications of leptin deficiency. 4 Metre leptin is not currently indicated for the treatment of partial lipodystrophy, liver disease, human immunodeficiency virus related lipodystrophy, or diabetes and hypertriglyceridemia without evidence of concurrent CGL or AGL. The starting daily dose of metreleptin varies by weight and sex (Table 1) , and daily dosing may be increased or decreased according to clinical response (changes in glycated hemoglobin [A1C], trig lycerides, etc.). Per the US prescribing label, metreleptin should be administered once daily (QD) at the same time every day. In clinical trial experience, the most common adverse reactions ($10% incidence) included headache, hypoglycemia, decreased weight, and abdominal pain.
There is limited experience using metreleptin to treat patients with GL in the clinic setting. Herein, we present the metrelep tin treatment experience in three patients with GL inadequately managed with conventional medications. Patients or their guard ians gave consent for the publication of this report.
paper subject to independent expert blind peer review. all editorial decisions made by independent academic editor. Upon submission manuscript was subject to antiplagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. this journal is a member of the Committee on publication ethics (Cope).
published by libertas academica. learn more about this journal. Table 1 ). These metabolic abnormalities were noted despite ongoing therapy with metformin 500 mg three times daily (TID), pioglitazone 30 mg QD, insulin detemir 40 U twice daily (BID), insulin aspart 40 U TID, fenofibrate 145 mg QD, niacin 500 mg QD, omega3 fatty acids 2 g TID, and orlistat 120 mg TID for four years.
Metreleptin was initiated at 5 mg QD subcutaneously by selfinjection. A1C and triglycerides were markedly improved at four weeks from 11.8% to 9.7% and 3675 to 2118 mg/dL, respectively ( Fig. 1) . At 12 weeks, while maintained at the same metreleptin dose, A1C and triglycerides dropped fur ther to normal levels (5.7% and 121 mg/dL, respectively), and slightly elevated ALT at baseline was within normal limits (23 U/L). The normalization of laboratory values occurred while the patient discontinued insulin aspart, pioglitazone, niacin, and fenofibrate (insulin detemir was decreased from 40 to 30 U BID, and the dosing frequency of omega3 fatty acids was reduced to QD). Weight remained stable, hepatomegaly and abdominal girth were reduced, and the patient reported resumption of regular menstrual cycles for the last two months. No adverse events (AEs) were noted.
Case Report 2
Patient 2 was a 10yearold female with CGL diagnosed from birth with a history of pancreatitis (four episodes requiring hospitalization), lytic bone lesions, and mesangial proliferative glomerulonephritis (Table 2 ). Prior to metreleptin treatment, she presented with generalized subcutaneous fat loss, acantho sis nigricans, elevated liver enzymes (ALT: 132 U/L; aspartate aminotransferase [AST]: 80 U/L), prominent abdomen due to hepatosplenomegaly (abdominal ultrasound demonstrated enlarged liver, homogeneous parenchyma, and decreased echogenicity), decreased energy, proteinuria (2.5 g/24 hours), and elevated A1C and triglycerides (9.2% and 497 mg/dL, respectively; Table 1 ). Her metabolic abnormalities were managed with metformin 500 mg/day, regular U100 insulin 1000 U/day, fenofibrate 200 mg/day, and enalapril 20 mg/day for 21 months.
Metreleptin was initiated at 4.2 mg/day while the patient was enrolled in research protocol 02DK0022 at the National Institutes of Health. At 24 weeks, A1C and triglycerides were reduced from 9.2% to 8.0% and 497 to 302 mg/dL, respec tively ( Fig. 1) , and the patient's proteinuria was resolved (0 g/24 hours). As A1C was still elevated, the patient's metre leptin and metformin doses were increased in a stepwise man ner over consecutive visits to 10 mg/day and 2000 mg/day, respectively. At week 168, the patient's metabolic parameters had improved (A1C: 6.6%; triglycerides: 84 mg/dL), and her total daily insulin requirement was reduced from 1000 to 75 U/day. ALT and AST were within normal limits (20 and 18 U/L, respectively). The patient's weight increased by 10%, and she selfreported improved energy levels, a flat abdomen, and that she completed her pubertal development with her first menses. No AEs were noted.
Case Report 3
Patient 3 was a 19yearold male with AGL manifesting between eight and nine years of age with panniculitis in the abdomen, legs, and face, followed later by generalized loss of subcutaneous fat (Table 2) . He presented with acanthosis nigricans, prominent abdomen, acromegaloid features, hyper phagia, asthenia, elevated liver enzymes (ALT: 171 U/L; AST: 81 U/L), hyperinsulinemia (fasting: 228 µU/mL), and elevated A1C and triglycerides (11.0% and 861 mg/dL, respectively). Abdominal ultrasound demonstrated an enlarged spleen and enlarged liver with smooth contour, hyperechoic texture, and no focal hepatic lesions. Metformin 500 mg/day was initi ated and titrated later to 2000 mg/day. High insulin levels persisted (,300 µU/mL) in parallel with worsening acantho sis, and he was started on regular U500 insulin 120 U/day (equivalent of regular U100 insulin 600 U/day). The patient was on this treatment regimen for seven years, and his last A1C measurement before metreleptin treatment was 11.8%. He was also managed with fenofibrate 200 mg/day, vitamin K 5 mg/month (due to vitamin K deficiency related to steato hepatitis), ranitidine 150 mg/day, ursodiol 300 mg/day, and enalapril 5 mg/day.
Metreleptin was initiated at 3.5 mg/day. At six weeks, the patient's A1C was reduced from 11.8% to 6.7% (Fig. 1) . At 32 weeks, A1C was further reduced to 5.1% and triglycerides were reduced to 36 mg/dL. At 96 weeks, his A1C increased to 5.8%. It was noted that the patient gained 6 kg of weight during this time, so the metreleptin dose was increased to 4 mg/day. As of the last measurement (week 140), A1C was 5.1% and triglycerides were 80 mg/dL. During treatment with metreleptin, the patient was able to discontinue the use of insulin and fenofibrate, remaining only on ursodiol 300 mg/day and enalapril 10 mg/day. ALT levels were reduced from 171 to 120 U/L, while AST remained stable (from 81 to 79 U/L). Followup hepatic ultrasonography indi cated increased spleen size with homogeneous structure and liver with rounded edges, enlarged, homogeneousincreased notes: a Most recent value was at age 12 and was decreased from 32.9 ng/ml at age 11. abbreviations: a1C, glycated hemoglobin; agl, acquired generalized lipodystrophy; alt, alanine aminotransferase; ast, aspartate aminotransferase; Bid, twice daily; CGL, congenital generalized lipodystrophy; F, female; FPG, fasting plasma glucose; M, male; N/A, not available; QD, once daily; TG, triglycerides; TID, three times daily; U, units.
echogenicity compatible with steatosis, no focal lesions, and dilated intra and extrahepatic bile ducts. The patient's weight increased from 61 to 67 kg with improvements in lean muscle mass observed. His appetite normalized allowing him to adhere to the recommended lowglucose diet for diabetes control, and his acanthosis nigricans was noted to have improved while on metreleptin. No AEs were noted, and the patient continues to remain on the same daily dose of metreleptin (4 mg/day).
discussion
All three patients with GL had significant metabolic abnor malities that were inadequately addressed with conventional glucose and lipidlowering therapies. Metreleptin was effec tive at normalizing very elevated A1C and triglycerides, with this response occurring as early as four to six weeks in Patients 1 and 3. Metreleptin dose was individualized to match changes in A1C and triglycerides, and concomitant medications were adjusted to avoid hypoglycemia. In parallel with improved metabolic parameters, all patients were able to either discon tinue or decrease their daily doses of insulin -an important point as patients with lipodystrophy sometimes require very high doses of insulin to maintain glycemic control. Only Patient 2 required an increase in metformin dose. Patients 1 and 3 were able to discontinue oral lipidlowering medi cations. High pill burden in conditions requiring longterm treatment has been associated with decreased adherence and quality of life (QoL). 5 The success of metreleptin therapy is dependent on good adherence to metreleptin and concomitant medications besides dietary modifications and other lifestyle changes. 6 Patients with lipodystrophy who are nonadherent to metreleptin and/or concomitant medications often experience relapses to previous metabolic derangements. [6] [7] [8] Metreleptin does not cure the underlying disorder of lipodystrophy but addresses the associated leptin deficiency; thus, most patients may require lifetime therapy.
Although difficult to quantify, patients with lipodystrophy may have decreased QoL 9 owing to the metabolic abnormali ties that they experience, particularly hyperphagia. Compli ance with diet may be difficult because of hunger related to the leptin deficiency, implying that hypothalamic satiety is also inhibited. During metreleptin treatment, Patients 1 and 3 reported marked reductions in hunger, and Patients 2 and 3 reported improved energy levels. While similar subjective find ings have been reported in at least one other cohort of patients with GL, 10 hyperphagia response to metreleptin has not been quantified in any previous clinical trials to date. Cosmetic dis figurement due to loss of adipose tissue and leptin deficiency can be very discouraging. In this case series, Patients 1 and 2 reported a less prominent abdomen or decreased girth during metreleptin treatment. The same patients also reported more regular menstrual cycles (Patient 1) or the achievement of first menses (Patient 2). Acanthosis nigricans was observed to have improved in Patients 2 and 3. Metreleptin is not approved for the treatment of hyperphagia or any other QoL parameters.
In addition to improved A1C and triglycerides, elevations of liver enzyme were numerically improved or normalized in all patients, with decreased size of hepatomegaly observed in Patient 1. At least one study group has described significant improvements in liver pathology from baseline with metre leptin treatment 11, 12 ; however, improved liver enzymes do not always correlate with improved liverrelated end points. 13 Patient 2 had proteinuria at baseline that resolved after metre leptin treatment. Metreleptin has been shown in a prior cohort of patients with GL to reduce urinary protein excretion in 11 of 15 patients treated for four months. 14 In the patients with GL presented here, metreleptin was effective at improving certain metabolic abnormalities in the clinic setting with no notable AEs. Subjective QoL improve ments (increased energy, normalization of appetite/menstrual function, improved appearance, etc.) are equally important to the patient treatment experience, as are improvements in laboratory parameters.
